# Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti

Source: https://onco.cc/trials/nct07549906/  
OnCo record `nct07549906` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine, fOLFOX (5-FU, leucovorin, oxaliplatin) and propranolol (Hemangeol) in colorectal cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study is a phase 2, randomised interventional study registered as NCT07549906 by Sun Yat-sen University, with a registry enrolment figure of 45 participants, started 2026-04-20 and due to reach its primary completion in 2026-07-31. Interventions recorded: Iparomlimab/Tuvonralimab; Capecitabine; Oxaliplatin; Propranolol. Conditions listed: Colon Cancer (Stage II &Amp; III); Immunotherapy; Beta Blocker; Neoadjuvant Chemoimmunotherapy. Primary outcome: Major Pathological Response (MPR). Colorectal eligibility wording from the registry: "Diagnosis / Stage: Histologically confirmed and radiologically assessed colon adenocarcinoma that is T4, or T3 with lymph node metastasis, with tumor location ≥10 cm from the anal verge, and clinical TNM staging per AJCC/UICC 8th edition". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07549906
- Phase: 2
- Setting: Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study
- Sponsor: Sun Yat-sen University
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07549906: https://clinicaltrials.gov/study/NCT07549906

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Propranolol (Hemangeol)](https://onco.cc/drugs/propranolol-hemangeol/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07549906.json